242 related articles for article (PubMed ID: 15372869)
1. Management of dyslipidemia in patients with metabolic syndrome.
Cziraky MJ
J Am Pharm Assoc (2003); 2004; 44(4):478-88; quiz 489-90. PubMed ID: 15372869
[TBL] [Abstract][Full Text] [Related]
2. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
Nesto RW
Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526
[TBL] [Abstract][Full Text] [Related]
3. Pharmacologic treatment of type 2 diabetic dyslipidemia.
Moon YS; Kashyap ML
Pharmacotherapy; 2004 Dec; 24(12):1692-713. PubMed ID: 15585439
[TBL] [Abstract][Full Text] [Related]
4. Fibrates in 2003: therapeutic action in atherogenic dyslipidaemia and future perspectives.
Chapman MJ
Atherosclerosis; 2003 Nov; 171(1):1-13. PubMed ID: 14642400
[TBL] [Abstract][Full Text] [Related]
5. Management of dyslipidemia in the metabolic syndrome: recommendations of the Spanish HDL-Forum.
Ascaso J; Gonzalez Santos P; Hernandez Mijares A; Mangas Rojas A; Masana L; Millan J; Pallardo LF; Pedro-Botet J; Perez Jimenez F; Pintó X; Plaza I; Rubiés J; Zúñiga M
Am J Cardiovasc Drugs; 2007; 7(1):39-58. PubMed ID: 17355165
[TBL] [Abstract][Full Text] [Related]
6. Niacin-based therapy for dyslipidemia: past evidence and future advances.
Ito MK
Am J Manag Care; 2002 Sep; 8(12 Suppl):S315-22. PubMed ID: 12240703
[TBL] [Abstract][Full Text] [Related]
7. Advances in the understanding and management of dyslipidemia: using niacin-based therapies.
Ito MK
Am J Health Syst Pharm; 2003 Jul; 60(13 Suppl 2):S15-21; quiz S25. PubMed ID: 12901026
[TBL] [Abstract][Full Text] [Related]
8. Optimal management of combined dyslipidemia: what have we behind statins monotherapy?
Tenenbaum A; Fisman EZ; Motro M; Adler Y
Adv Cardiol; 2008; 45():127-153. PubMed ID: 18230960
[TBL] [Abstract][Full Text] [Related]
9. The metabolic basis of atherogenic dyslipidemia.
Vinik AI
Clin Cornerstone; 2005; 7(2-3):27-35. PubMed ID: 16473258
[TBL] [Abstract][Full Text] [Related]
10. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
Cziraky MJ; Watson KE; Talbert RL
J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
[TBL] [Abstract][Full Text] [Related]
11. Statins and diabetes.
Carmena R; Betteridge DJ
Semin Vasc Med; 2004 Nov; 4(4):321-32. PubMed ID: 15861314
[TBL] [Abstract][Full Text] [Related]
12. The metabolic syndrome: pathophysiology, clinical relevance, and use of niacin.
Ito MK
Ann Pharmacother; 2004 Feb; 38(2):277-85. PubMed ID: 14742767
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic implications of recent ATP III guidelines and the important role of combination therapy in total dyslipidemia management.
Boden WE
Curr Opin Cardiol; 2003 Jul; 18(4):278-85. PubMed ID: 12858126
[TBL] [Abstract][Full Text] [Related]
14. Nicotinic acid in the management of dyslipidaemia associated with diabetes and metabolic syndrome: a position paper developed by a European Consensus Panel.
Shepherd J; Betteridge J; Van Gaal L;
Curr Med Res Opin; 2005 May; 21(5):665-82. PubMed ID: 15969866
[TBL] [Abstract][Full Text] [Related]
15. Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: therapeutic options beyond statins.
Tenenbaum A; Fisman EZ; Motro M; Adler Y
Cardiovasc Diabetol; 2006 Sep; 5():20. PubMed ID: 17002798
[TBL] [Abstract][Full Text] [Related]
16. Diabetic dyslipidemia.
Kreisberg RA
Am J Cardiol; 1998 Dec; 82(12A):67U-73U; discussion 85U-86U. PubMed ID: 9915665
[TBL] [Abstract][Full Text] [Related]
17. Niacin as a component of combination therapy for dyslipidemia.
Miller M
Mayo Clin Proc; 2003 Jun; 78(6):735-42. PubMed ID: 12934785
[TBL] [Abstract][Full Text] [Related]
18. Treating dyslipidemic patients with lipid-modifying and combination therapies.
Worz CR; Bottorff M
Pharmacotherapy; 2003 May; 23(5):625-37. PubMed ID: 12741437
[TBL] [Abstract][Full Text] [Related]
19. Insulin resistance syndrome and type 2 diabetes mellitus.
Erkelens DW
Am J Cardiol; 2001 Oct; 88(7B):38J-42J. PubMed ID: 11595198
[TBL] [Abstract][Full Text] [Related]
20. Lipoprotein abnormalities and their consequences for patients with type 2 diabetes.
Krentz AJ
Diabetes Obes Metab; 2003 Nov; 5 Suppl 1():S19-27. PubMed ID: 14984018
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
